Current issues in non-inferiority trials

Statistics in Medicine

Volumn 27, Issue 3, 2008, Pages 317-332

  Fleming, Thomas R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Active control trial; Bio creep; Equivalence trial; Imputed placebo; Margin

Indexed keywords

ACETYLSALICYLIC ACID; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANALGESIC AGENT; ANTIBIOTIC AGENT; CELECOXIB; CLOPIDOGREL; DOCETAXEL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; IFOSFAMIDE; NAPROXEN; NAVELBINE; PEMETREXED; PLACEBO; VANCOMYCIN; VORICONAZOLE;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIGESTIVE SYSTEM ULCER; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FALSE POSITIVE RESULT; FEBRILE NEUTROPENIA; HAZARD RATIO; HOSPITAL INFECTION; HUMAN; LUNG NON SMALL CELL CANCER; METHODOLOGY; MONOTHERAPY; OSTEOARTHRITIS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZATION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; SYSTEMATIC ERROR; VALIDITY;

CLINICAL TRIALS AS TOPIC; DRUG THERAPY; ENDPOINT DETERMINATION; HUMANS; ODDS RATIO; PLACEBOS; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES;

EID: 38949173080     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2855     Document Type: Article

References (32)

1. ICH E-9. International Conference on Harmonisation: Statistical Principles for Clinical Trials. Published in the Federal Register of 9 May 1997 (62 FR 25712).
2. ICH E-10. International Conference on Harmonisation: Choice of Control Group in Clinical Trials. Published U.S. May 2001. http://www.fda.gov/cder/guidance/index.htm
3. Temple R. Difficulties in evaluating positive control trials. Proceedings of the American Statistical Association, Biopharmaceutical Section, 1983; Section I:1-7.
4. Fleming TR. Treatment evaluation in active control studies. Cancer Treatment Reports 1987; 71:1061-1065.
5. Hung HMJ, Wang SJ, Tsong Y, Lawrence J, O'Neil RT. Some fundamental issues with non-inferiority testing in active controlled trials. Statistics in Medicine 2003; 22:213-225.
6. Hung HMJ, Wang SJ, O'Neill RT. A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials. Biometrical Journal 2005; 1:28-36.
7. Fleming TR. Evaluation of active control trials in acquired immune deficiency syndrome. Journal of AIDS 1990; 3(Suppl. 2):82-87.
8. Temple R, Ellenberg S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Annals of Internal Medicine 2000; 133:455-463.
9. Ellenberg S. Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases. Annals of Internal Medicine 2000; 133:464-470.
10. Fleming TR. Design and interpretation of equivalence trials. American Heart Journal 2000; 139:S171-Sl76.
11. Hasselblad V, Kong DF. Statistical methods for comparison to placebo in active-controlled trials. Drug Information Journal 2001; 35:435-449.
12. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW, the CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT Statement. JAMA 2006; 295:1152-1160.
13. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Annals of Internal Medicine 2006; 145:62-69.
14. Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: a randomized trial. Lancet 1999; 353:429-438.
15. FDA Cardio-renal Drugs Advisory Committee Briefing Document. Hirudin in acute coronary syndrome. 90th Meeting of the FDA Cardio-renal Advisory Committee, 2 May 2000. www.fda.gov/ohrms/dockets/ac/00/ transcripts/3612t2.rtf
16. FDA Oncology Drugs Advisory Committee Briefing Document. NDA 21-677. Alimta as Single Agent is Indicated for Treatment of Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) After Prior Chemotherapy. Eli Lilly and Company, 27 July 2004. www.fda.gov/ ohrms/dockets/ac/04/briefing/2004-4060bl.htm
17. TAX 317, Shepherd FA, Dancey J et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Journal of Clinical Oncology 2000; 18(10):2095-2103.
18. TAX 320, Fassella FV, DeVore R et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum containing chemotherapy regimens. Journal of Clinical Oncology 2000; 18(12):2354-2362.
19. Lincoff AM, Bittl JA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE 2 randomized trial. JAMA 2003; 289(7):853-863.
20. EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998; 352:87-92.
21. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000; 356:2037-2044.
22. Snapinn SM. Alternatives for discounting in the analysis of noninferiority trials. Journal of Biopharmaceutical Statistics 2004; 14(2):263-273.
23. FDA Anti-Infective Drugs Advisory Committee Briefing Information. Approach for Selection of Delta in Non-inferiority (Equivalence) Clinical Trials. 19 February 2002.
24. Pizzo PA, Robichaud KJ, Gill FA et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. American Journal of Medicine 1982; 72:101-111.
25. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. American Journal of Medicine 1989; 86:668-672.
26. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. New England Journal of Medicine 1999; 340:764-771.
27. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. New England Journal of Medicine 2002; 346(4):225-234.
28. de Pauw BE, Sable CA, Walsh TJ, Lupinacci RJ, Bourque MR, Wise BA, Nguyen BY, DiNubile MJ, Teppler H. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. Transplant Infectious Disease 2006; 8:31-37.
29. FDA Anti-Infective Drugs Advisory Committee. Factive (gemifloxacin mesylate) Tablets for treatment of acute bacterial sinusitis. Transcript for 12 September 2006 Meeting. http://www.fda.gov/ ohrms/dockets/ac/cder06.html#AntiInfective
30. FDA Anti-Infective Drugs Advisory Committee. KETEK (telithromycin) for acute bacterial exacerbations of chronic bronchitis, acute bacterial sinusitis, and community acquired pneumonia. Transcript for 14-15 December 2006 Meeting. http://www.fda.gov/ohrms/dockets/ac/ cder06.html#AntiInfective
31. Jorgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared with industry supported meta-analysis and other meta-analysis of the same drugs: systematic review. British Medical Journal 2006; 333:782-786.
32. Rothmann M, Li N, Chen G, Chi GY, Temple R. Tsou HH. Design and analysis of non-inferiority mortality trials in oncology. Statistics in Medicine 2003; 22(2):239-264.